Scholarlink

Background <p>Endothelial dysfunction is a hallmark of sickle vasculopathy. Thrombomodulin (THBD) is a transmembrane protein expressed on vascular endothelial cells suppressing blood coagulation and exerting anti-inflammatory effects. It is a known biomarker of endothelial injury and its elevated serum levels with subsequently, reduced endothelial function have been implicated in various disorders.</p> <p>We aimed to quantify THBD plasma levels in a cohort of Egyptian patients with SCD and investigate THBD levels’ association with disease severity and other inflammatory markers.</p> Methods <p>Plasma THBD levels were measured for 70 SCD patients and 70 healthy control subjects using an Enzyme-Linked Immunosorbent Assay (ELISA) kit that captures all THBD domains. Patients’ demographic, clinical, and laboratory characteristics were retrieved from their archived files.</p> Results <p>The mean THBD plasma level of our studied SCD patients was 5.23 ± 3.05&#xa0;ng/ml (range 1.25–16.56&#xa0;ng/ml) and it was significantly higher in comparison to controls (<i>p</i>-value = 0.001). Thrombomodulin levels were elevated in SCD patients experiencing SCD-related complications and those requiring hospital admissions, denoting disease severity (<i>p</i>-value = 0.004 and 0.017, respectively). A significant positive correlation was observed between thrombomodulin levels and patients’ age (<i>r</i> = 0.359, <i>p</i>-value = 0.002). However, there were no statistically significant correlations with HbF (<i>p</i> = 0.075) between thrombomodulin levels and the studied laboratory parameters in our SCD patients (<i>p</i>-value &gt; 0.05).</p> Conclusion <p>Steady-state SCD patients exhibited higher thrombomodulin plasma levels than controls. Thrombomodulin levels may increase with age and might be applied as a marker of disease severity among patients with SCD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of thrombomodulin (THBD) plasma levels in sickle cell disease and correlation with disease severity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月20日

查看全文
  • Yasmeen M.M. Selim,
  • Amina Abdelsalam,
  • Eman A. Youssef,
  • Abdelkarem Bahy,
  • Dalia El-Sayed

摘要

Background

Endothelial dysfunction is a hallmark of sickle vasculopathy. Thrombomodulin (THBD) is a transmembrane protein expressed on vascular endothelial cells suppressing blood coagulation and exerting anti-inflammatory effects. It is a known biomarker of endothelial injury and its elevated serum levels with subsequently, reduced endothelial function have been implicated in various disorders.

We aimed to quantify THBD plasma levels in a cohort of Egyptian patients with SCD and investigate THBD levels’ association with disease severity and other inflammatory markers.

Methods

Plasma THBD levels were measured for 70 SCD patients and 70 healthy control subjects using an Enzyme-Linked Immunosorbent Assay (ELISA) kit that captures all THBD domains. Patients’ demographic, clinical, and laboratory characteristics were retrieved from their archived files.

Results

The mean THBD plasma level of our studied SCD patients was 5.23 ± 3.05 ng/ml (range 1.25–16.56 ng/ml) and it was significantly higher in comparison to controls (p-value = 0.001). Thrombomodulin levels were elevated in SCD patients experiencing SCD-related complications and those requiring hospital admissions, denoting disease severity (p-value = 0.004 and 0.017, respectively). A significant positive correlation was observed between thrombomodulin levels and patients’ age (r = 0.359, p-value = 0.002). However, there were no statistically significant correlations with HbF (p = 0.075) between thrombomodulin levels and the studied laboratory parameters in our SCD patients (p-value > 0.05).

Conclusion

Steady-state SCD patients exhibited higher thrombomodulin plasma levels than controls. Thrombomodulin levels may increase with age and might be applied as a marker of disease severity among patients with SCD.